News

2022.04.20

Dr. Hatou presented Cellusion business progress in the 2022 Cell & Gene Meeting on the Med.

Barcelona, Spain (April 20-22, 2022)-, Dr. Hatou, founder & CEO of Cellusion Inc., presents recent business progress in the 2022 Cell & Gene Meeting on the Med. The Cell & Gene Meeting on the Mesa is well known an international conference organized by the Alliance for Regenerative Medicine, where many pharmaceutical, startup, and academic organizations working on the social implementation of regenerative medicine gather to discuss on various issues. Cellusion is happy to participate in this international community of regenerative medicine and accelerate our research program to deliver novel therapies for bullous keratopathy patients all over the world.

About the Cell & Gene Meeting on the Med,
https://meetingonthemed.com/

[About Cellusion Inc.]
Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi Cells. Cellusion’s mission is to a community the clear vision of the future with cellular technology breakthrough.

Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: 1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded: January 2015
URL: https://cellusion.jp/en/

For further information: please ask us through the contact form on our website.

COPYRIGHT CELLUSION ALL RIGHTS RESERVED.